Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

while being agnostic for the FGFR3 gatekeeper mutations. TYRA-300 is expected to be evaluated in three Phase 2 studies: SURF302 for IR NMIBC, BEACH301 for pediatric achondroplasia and SURF301 for ...

Nina S. Kjellson, a director at Tyra Biosciences , Inc. (NASDAQ:TYRA), recently sold shares of the company's common stock totaling $74,323. The timing of this insider sale comes as the stock trades ...

This receptor tyrosine kinase plays a vital role in controlling cellular growth and differentiation, and activating FGFR3 mutations or fusions are frequently observed in NMIBC, especially in papillary ...

Tasurgratinib (also known as E-7090) is an oral selective FGFR1, FGFR2, and FGFR3 inhibitor that, if approved, will join other drugs in the class on the market, including Incyte’s Pemazyre ...

28 If both parents have achondroplasia, then testing the pregnancy for homozygosity or compound heterozygosity for mutations in FGFR3 is readily available, because 97% of patients with ...

They can significantly decrease the invasiveness of bladder cancer cells, making them especially suitable for patients with FGFR3 mutations or abnormal activation of the MAPK pathway. Immune ...

Six genes were detected as differentially expressed in all four studies (including the present one): AGR2, CEACAM5, CLDN3, CK18, EpCAM and FGFR3. In addition ... circulating clones may carry bad ...

The National Comprehensive Cancer Network recommends that all patients with stage IVA and stage IVB urothelial carcinoma have molecular analysis that integrates at least FGFR3 testing to help ...

In this study, which appears in Nature, experiments showed that the gene mutation in a calcium signaling pathway enhances endosymbiosis in farming conditions. Excitingly, the team used genetic ...